Reference SummaryPoliti K, Oncogene 2004 Feb 26;23(8):1558-65

Title

'Designer' tumors in mice.

Authors

Politi K; Kljuic A; Szabolcs M; Fisher P; Ludwig T; Efstratiadis A

Journal

Oncogene

Volume

23

Issue

8

Year

2004

Pages

1558-65

Abstract

We have developed and tested successfully a general method based on Cre-mediated recombination that can be used for ubiquitous or tissue-specific expression of protein products, including tumor-inducing oncoproteins. Depending on the specificity of a chosen promoter driving cre expression, tumors develop by design in bitransgenic mouse progeny derived by crossing Cre-producing mice with partners carrying a dormant oncogenic transgene (targeted into the 3' noncoding region of the cytoplasmic beta-actin locus) that becomes functional after excision of a 'floxed' DNA segment. To provide proof-of-principle, we have used as models transgenes encoding the polyomavirus middle T antigen (PVMT) and the T antigens of the SV40 early region (SVER). Cre-dependent activation of widespread SVER expression resulted in hyperplasias or invasive tumors affecting particular visceral smooth muscles, whereas Cre-dependent, mammary gland-specific expression of PVMT-induced adenocarcinomas, according to plan. Unexpectedly, we also encountered spontaneous (Cre-independent) oncogene expression occurring as a rare event, which simulates the initiation of sporadic tumors and leads to PVMT-induced hemangiomas and mammary carcinomas or SVER-induced disseminated sarcomas, thus, revealing particular tissue susceptibilities to the actions of these oncoproteins.

Links

J:87544 – MGI References
14661057 – National Library of Medicine/PubMed

Models

Strain Model Name Treatment Agent(s) Organ Affected Frequency Model Details
B6;129S1-Actbtm1(PyVT)Arge/+ Waptm1(cre)Arge/+ Blood vessel hemangioma Blood vessel

70.58 - 96.97

129S1/Sv-Actbtm1(PyVT)Arge/+ Blood vessel hemangioma Blood vessel

50.48 - 100

129S1/Sv-Actbtm1(PyVT)Arge/+ Blood vessel hemangioma Lung

observed

129S1/Sv-Actbtm1(PyVT)Arge/+ Blood vessel hemangioma Liver

observed

129S1/Sv-Actbtm1(PyVT)Arge/+ Blood vessel hemangioma Uterus

observed

129S1/Sv-Actbtm1(PyVT)Arge/+ Blood vessel hemangioma - cavernous Blood vessel

very high

129S1/Sv-Actbtm1(PyVT)Arge/+ Blood vessel hemangioma - sclerosing Blood vessel

observed

129S1/Sv-Actbtm1(PyVT)Arge/+ Blood vessel hemangiosarcoma Lung

8.33

B6;129S1-Actbtm1(PyVT)Arge/+ Waptm1(cre)Arge/+ Liver carcinoma - undifferentiated Liver

2 - 3.03

129S1/Sv-Actbtm1(PyVT)Arge/+ Mammary gland adenocarcinoma Mammary gland

75

B6;129S1-Actbtm1(PyVT)Arge/+ Waptm1(cre)Arge/+ Mammary gland adenocarcinoma - intraductal Mammary gland

30 - 88.24

129S1/Sv-Actbtm1(PyVT)Arge/+ Mammary gland adenofibroma Mammary gland

8.33

129S1-Actbtm2(Tag)Arge Mesodermal cell/mesoblast sarcoma Mesodermal cell/mesoblast

high

129S1-Actbtm2(Tag)Arge Mesodermal cell/mesoblast sarcoma - undifferentiated Mesodermal cell/mesoblast

100

129S1-Actbtm2(Tag)Arge Mesodermal cell/mesoblast sarcoma - undifferentiated Liver

high

129S1-Actbtm2(Tag)Arge Mesodermal cell/mesoblast sarcoma - undifferentiated Spleen

high

129S1-Actbtm2(Tag)Arge Mesodermal cell/mesoblast sarcoma - undifferentiated Thoracic cavity

high

129S1-Actbtm2(Tag)Arge/+ Mesodermal cell/mesoblast sarcoma - undifferentiated Mesodermal cell/mesoblast

high - 100

129S1-Actbtm2(Tag)Arge/+ Mesodermal cell/mesoblast sarcoma - undifferentiated Liver

high

129S1-Actbtm2(Tag)Arge/+ Mesodermal cell/mesoblast sarcoma - undifferentiated Spleen

high

129S1-Actbtm2(Tag)Arge/+ Mesodermal cell/mesoblast sarcoma - undifferentiated Thoracic cavity

high

B6;129S1-Actbtm1(PyVT)Arge/+ Waptm1(cre)Arge/+ Spleen carcinoma - undifferentiated Spleen

2 - 3.03

B6;129S1-Actbtm1(PyVT)Arge/+ Waptm1(cre)Arge/+ (Unspecified organ) tumor (Unspecified organ)

100